References
- Bronchud MH, Foote MA, Giaccone G, Olapade O, Workman P (Eds). Principles of Molecular Oncology, Humana Press, Totowa NJ, Second Edition, 2003.
- Workman P. Strategies for treating cancers caused by multiple genomic abnormalities: From concepts to cures? Curr Opin Invest Drugs 2003; 4, 12: 1410-1415.
- Garrett MD, Workman P. Discovering novel chemother-apeutic agents for the Third Millennium. Eur J Cancer 1999; 35: 2010–2030.
- Workman P. The opportunities and challenges of per-sonalised genome-based molecular therapies for cancer: Targets, technologies and molecular chaperones. Cancer Chemother Pharmacol 2003; 52 (Supplement 1): S45-S56.
- Workman P. The impact of genomic and proteomic technologies on the development of new cancer drugs. Ann Oncol 2002; 4: 115–124.
- Aherne GW, McDonald E, Workman P. Finding the needle in the haystack: Why high-throughput screening is good for your health. Breast Cancer Res 2002; 4: 148–154.
- Clarke PA, Te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacolo-gy and drug development: Progress and potential. Biochem Pharmacol 2001; 62: 1311–1336.
- Workman P. How much get there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Design 2003; 9: 891–902.
- Davies H, Signe11 GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2001; 417: 949–954.
- Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) inhibits retinoblatoma protein phosphorylation, causes loss of cyclin D1 and activates the mitogen-activated protein kinase pathway. Cancer Res 2004; 64: 262–272.
- Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Transac 2004; 32 (2): 393–396.
- Maloney A, Workman P. Hsp90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002; 2: 3–24.
- Kristeleit R, Stimson L, Workman P, Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 2004; 9 (1): 135–154.
- Rowlands MG, Newbatt YM, Turlais F, et al. High throughput screening assay for inhibitors of heat-shock protein 90 (Hsp90) ATpase activity. Anal Biochem 2004; 327: 176–183.
- Dymock B, Drysdale M, McDonald E, Workman P. Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin Therap Patents 2004; 837–847.
- Wright L, Barril X, Dymock B, et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 iso-forms. Chem Biol 2004; 11: 775–785.
- Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of colon adenocarcinoma cells following inhibition of signal transduction by 17-allylamino-17-demethoxygel-danamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 2000; 19: 4125-4133.
- Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of Hsp90 by Ahal, a novel stress-regulat-ed co-chaperone. Mol Cell 2002; 10: 1307-1318.
- Chung Y-L, Troy H, Banerji U, et al. Magnetic reso-nance spectroscopic pharmacodynamic markers of Hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, in human colon cancer models. J Natl Cancer Inst 2003; 95: 1624-1633.
- Raynaud Fl, Fischer PM, Nutley BP, et al. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by paral-lel synthesis. Mol Cancer Ther 2004; 3: 353–362.